{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T18:07:07Z","timestamp":1789495627161,"version":"build-2803163510"},"reference-count":27,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T00:00:00Z","timestamp":1776211200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000871","name":"Mayo Clinic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007048","name":"Mayo Clinic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007048","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Oncology"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.omton.2026.201209","type":"journal-article","created":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T00:13:02Z","timestamp":1776384782000},"page":"201209","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["CAR-T cells directed toward PD-L1 demonstrate potent, antigen-specific activity against cholangiocarcinoma: A proof of concept study"],"prefix":"10.1016","volume":"34","author":[{"given":"Piyush","family":"Gondaliya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adil Ali","family":"Sayyed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dylan A.","family":"Zinn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaqing","family":"Qie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene K.","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Driscoll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parthvi B.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuhua","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7021-9532","authenticated-orcid":false,"given":"Tushar","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omton.2026.201209_bib1","doi-asserted-by":"crossref","first-page":"24644","DOI":"10.18632\/oncotarget.15602","article-title":"PD-L1 expression in perihilar and intrahepatic cholangiocarcinoma","volume":"8","author":"Fontugne","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.omton.2026.201209_bib2","article-title":"PD-L1 Expression in Biliary Tract Cancer: Comparison across Antibody Clones and Role as a Predictor of Response to Chemoimmunotherapy: A Meta-Analysis","volume":"9","author":"Juarez-Vignon Whaley","year":"2025","journal-title":"JCO Prec. Oncol."},{"key":"10.1016\/j.omton.2026.201209_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2021.173960","article-title":"Inhibition of T-cell-mediated immune response via the PD-1\/PD-L1 axis in cholangiocarcinoma cells","volume":"897","author":"Suriyo","year":"2021","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.omton.2026.201209_bib4","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.1037646","article-title":"Durable response to the combination of pembrolizumab and nab-paclitaxel in a metastatic extrahepatic cholangiocarcinoma: A case report and literature review","volume":"13","author":"Tan","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.omton.2026.201209_bib5","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1186\/s12885-022-10373-1","article-title":"A phase II single arm study of Nivolumab with stereotactic Ablative radiation Therapy after induction chemotherapy in CHOlangiocarcinoma (NATCHO)","volume":"22","author":"Elias","year":"2022","journal-title":"BMC Cancer"},{"key":"10.1016\/j.omton.2026.201209_bib6","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200015","article-title":"Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer","volume":"1","author":"Oh","year":"2022","journal-title":"NEJM Evid."},{"key":"10.1016\/j.omton.2026.201209_bib7","doi-asserted-by":"crossref","DOI":"10.1172\/JCI152670","article-title":"Multicenter randomized phase II trial of atezolizumab with or without cobimetinib in biliary tract cancers","volume":"131","author":"Yarchoan","year":"2021","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.omton.2026.201209_bib8","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1321813","article-title":"The predictive value of PD-L1 expression in response to anti-PD-1\/PD-L1 therapy for biliary tract cancer: a systematic review and meta-analysis","volume":"15","author":"Yoon","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omton.2026.201209_bib9","article-title":"Efficacy and safety of anti-PD1\/PDL1 in advanced biliary tract cancer: a systematic review and meta-analysis","volume":"13","author":"Jiang","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omton.2026.201209_bib10","doi-asserted-by":"crossref","first-page":"181","DOI":"10.36401\/JIPO-25-X3","article-title":"Anti\u2013PD-1 Therapy for Patients with Advanced Cholangiocarcinoma: Ready for Prime Time?","volume":"8","author":"Brar","year":"2025","journal-title":"J. Immunother. Precis. Oncol."},{"key":"10.1016\/j.omton.2026.201209_bib11","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s40364-020-00212-5","article-title":"Resistance to PD-1\/PD-L1 blockade cancer immunotherapy: mechanisms, predictive factors, and future perspectives","volume":"8","author":"Sun","year":"2020","journal-title":"Biomark. Res."},{"key":"10.1016\/j.omton.2026.201209_bib12","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.3390\/cancers15133312","article-title":"Immunotherapy in biliary tract cancers: current standard-of-care and emerging strategies","volume":"15","author":"Lo","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.omton.2026.201209_bib13","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1200\/OP.22.00819","article-title":"Chimeric antigen receptor T-cell therapy for hematologic malignancies: a practical review","volume":"19","author":"Strati","year":"2023","journal-title":"JCO Oncol. Pract."},{"key":"10.1016\/j.omton.2026.201209_bib14","article-title":"The efficacy and safety of CD7 chimeric antigen receptor T-cell therapy for hematologic malignancies: a systematic review and meta-analysis","volume":"14","author":"Liu","year":"2024","journal-title":"Front. Oncol."},{"key":"10.1016\/j.omton.2026.201209_bib15","article-title":"Solid cancer-directed CAR T cell therapy that attacks both tumor and immunosuppressive cells via targeting PD-L1","volume":"32","author":"Luo","year":"2024","journal-title":"Mol. Ther. Oncol."},{"key":"10.1016\/j.omton.2026.201209_bib16","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s12951-021-01213-8","article-title":"3D hanging spheroid plate for high-throughput CAR T cell cytotoxicity assay","volume":"20","author":"Chen","year":"2022","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.omton.2026.201209_bib17","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.898732","article-title":"Methods for establishing a renal cell carcinoma tumor spheroid model with immune infiltration for immunotherapeutic studies","volume":"12","author":"Lugand","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.omton.2026.201209_bib18","doi-asserted-by":"crossref","first-page":"6154","DOI":"10.1038\/s41598-022-09964-6","article-title":"Combination gemcitabine and PD-L1xCD3 bispecific T cell engager (BiTE) enhances T lymphocyte cytotoxicity against cholangiocarcinoma cells","volume":"12","author":"Wathikthinnakon","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.omton.2026.201209_bib19","article-title":"Immune microenvironment of cholangiocarcinoma: Biological concepts and treatment strategies","volume":"14","author":"Yu","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omton.2026.201209_bib20","doi-asserted-by":"crossref","first-page":"561","DOI":"10.3389\/fphar.2017.00561","article-title":"PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: mechanism, combinations, and clinical outcome","volume":"8","author":"Alsaab","year":"2017","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.omton.2026.201209_bib21","doi-asserted-by":"crossref","first-page":"137","DOI":"10.3892\/ijo.2023.5585","article-title":"Tumor immune microenvironment and the current immunotherapy of cholangiocarcinoma","volume":"63","author":"Yang","year":"2023","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.omton.2026.201209_bib22","doi-asserted-by":"crossref","DOI":"10.1002\/cti2.1154","article-title":"Severe delayed pulmonary toxicity following PD-L1\u2013specific CAR-T cell therapy for non-small cell lung cancer","volume":"9","author":"Liu","year":"2020","journal-title":"Clin. Transl. Immunol."},{"key":"10.1016\/j.omton.2026.201209_bib23","doi-asserted-by":"crossref","first-page":"7199","DOI":"10.18632\/aging.202578","article-title":"APDL1-CART cells exhibit strong PD-L1-specific activity against leukemia cells","volume":"13","author":"Peng","year":"2021","journal-title":"Aging (Albany NY)"},{"key":"10.1016\/j.omton.2026.201209_bib24","doi-asserted-by":"crossref","first-page":"2762","DOI":"10.1016\/j.ymthe.2024.06.006","article-title":"Targeting PD-L1 in cholangiocarcinoma using nanovesicle-based immunotherapy","volume":"32","author":"Gondaliya","year":"2024","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omton.2026.201209_bib25","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.nucmedbio.2021.05.004","article-title":"Non-invasive immunoPET imaging of PD-L1 using anti-PD-L1-B11 in breast cancer and melanoma tumor model","volume":"100\u2013101","author":"Bansal","year":"2021","journal-title":"Nucl. Med. Biol."},{"key":"10.1016\/j.omton.2026.201209_bib26","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1158\/1078-0432.CCR-22-2038","article-title":"Favorable activity and safety profile of memory-enriched CD19-targeted chimeric antigen receptor T-cell therapy in adults with high-risk relapsed\/refractory ALL","volume":"29","author":"Aldoss","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omton.2026.201209_bib27","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.1021\/acs.molpharmaceut.1c00213","article-title":"MiR-155 inhibitor-laden exosomes reverse resistance to cisplatin in a 3D tumor spheroid and xenograft model of oral cancer","volume":"18","author":"Sayyed","year":"2021","journal-title":"Mol. Pharm."}],"container-title":["Molecular Therapy Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950329926000858?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950329926000858?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T08:21:11Z","timestamp":1783326071000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950329926000858"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S2950329926000858"],"URL":"https:\/\/doi.org\/10.1016\/j.omton.2026.201209","relation":{},"ISSN":["2950-3299"],"issn-type":[{"value":"2950-3299","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CAR-T cells directed toward PD-L1 demonstrate potent, antigen-specific activity against cholangiocarcinoma: A proof of concept study","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omton.2026.201209","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"201209"}}